Microenvironmental factors originating from RAS-mutated cancer stem cells stimulated an angiogenic feedback loop with the surrounding environment causing the expression of leptin and TGF-β receptors on the cancer stem cells. Most significantly, leptin and TGF-β signaling were required for malignant transformation.
The findings, which were published in the Nov. 30, 2022 issue of Nature, raise “the intriguing possibility that many cancer mutations may function to lock into place, rather than set the course of, a path that is predetermined by aberrant crosstalk between a cancer stem cell and its microenvironment,” said senior author Elaine Fuchs, Rebecca C. Lancefield Professor and Howard Hughes Medical Institute investigator at Rockefeller University.
Several studies have indicated that volatile organic compounds (VOCs) in exhaled breath can be altered by lung cancer and serve as identifiable biomarkers. A limitation of using these VOCs as clinical biomarkers has been the fact that hundreds of such molecules are present in exhaled breath and it is experimentally challenging to monitor the molecular concentration changes of all the VOCs and further use them in lung cancer detection.
In a study published on Nov. 30, 2022, in PLOS One, researchers at the University of Louisville, Kentucky, and Indian Council of Agricultural Research (ICAR), New Delhi, analyzed the metabolic carbonyl compounds present in exhaled breath of the patients and developed a machine learning approach involving relevant VOC selection and use in cancer patient classification model training. Read More
Researchers from The Hospital for Sick Children have created mouse models related to autism. Nine novel models related to autism were produced in C57BL/6NCrl (B6N) mice using loss-of-function mouse lines with knockout of genes Katnal2, L2hgdh, Nexmif, Otc, Pah, Rab39b, Ranbp17, Upf3b and Ypel2. Read More
Researchers at St. Louis University, Washington University in St. Louis, and Fimbrion Therapeutics Inc. have identified ubiquinol-cytochrome C reductase cytochrome b subunit (qcrB) (Mycobacterium tuberculosis) inhibitors reported to be useful for the treatment of tuberculosis. Read More
Researchers from Anhui Medical University published data from a study that aimed to assess the antifibrotic effects of the transforming growth factor-β (TGF-β) receptor type I (TGFBR1/ALK5) inhibitor Cpd-0225. Read More
Researchers from Shouyao Holdings (Beijing) Co. Ltd. presented the discovery of novel Wee1-like protein kinase inhibitors being investigated as agents for the treatment of cancer. Read More
University College Cardiff has divulged heteroaryl compounds acting as GABA(A) receptor subunit α5 (GABRA5) negative allosteric modulators reported to be useful for the treatment of cognitive disorders. Read More
Opus Genetics Inc. has received FDA clearance for its IND application for a first-in-human phase I/II trial of OPGX-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). The trial is due to start in the U.S. early next year (ClinicalTrials.gov Identifier NCT05616793). Read More
Sparingvision SAS has obtained FDA clearance for its IND application for SPVN-06, its lead gene-independent therapy for the treatment of retinitis pigmentosa (RP). SparingVision has also submitted a clinical trial authorization (CTA) application to the French regulator (ANSM), which is currently under review. Read More
George Washington University has described N-ACYL fosmidomycin prodrug analogues acting as 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr; IspC) (Mycobacterium tuberculosis) and Dxr (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria and tuberculosis. Read More
